



**Massachusetts Department of Public Health**

**MA PMP IGNITE Session:  
The Massachusetts Prescription  
Monitoring Program (MA PMP)**

**PDMP Administrators' National Meeting  
San Antonio, Texas, May 7-9, 2024**

**Rodd Kelly**

**MA PMP Systems Administrator**

# Welcome

This presentation is provided by the Massachusetts Prescription Monitoring System. Our PMP is within the Drug Control Program under the remit of Department of Public Health.

- Brief Program Highlights
- Utilization
- Compliance
- Data Submission Error Report
- Data Quality
- MassPAT Registration
- Buprenorphine Prompt
- Stimulant Analyses
- Activity of Concern
- Future Initiatives


# Brief Program Highlights

- Transition to ASAP 5.2B
- Notification to non-compliant Prescribers who are not registered in MassPAT
- SafeScripts+ evaluation
- Publication of integration manuscript
- BSAS/BU scope of pain (MassPAT demo)

# MassPAT Utilization

## Patient Search Events


The MA PMP has noted a marked increase and transition in utilization and access through integrated Healthcare Facilities. Integration began in 2018.



# Integration Utilization

- Over the past 6 months (October 2023-March 2024):
  - 499 licenses have made a request.
  - 89 new licenses approved.
  - Over 3 million successful patient searches.
- Integration has been a key reason for the rise in utilization.
- In October 2021 integration searches surpassed web portal searches.

# Integration Utilization (Continued)




Source: MDPH, MA PMP

# Data Submission Compliance

## Delinquency


Regarding delinquency in pharmacy reporting, the 1188 pharmacies registered in MA are currently 100% compliant in prescription record reporting according to the latest reports. Delinquency outreach is accomplished by phone and email, usually once the pharmacy reaches 5 days of delinquency.



# Data Submission Error Report

## Error Management

A Dispenser Error Report is pulled daily from Tableau. Pharmacies and vendors are contacted to offer reporting guidance. Of the 80 pharmacies reporting from across the country on the current report, 68 have 10 or less records with errors.



Source: MDPH, MA PMP



# Data Quality

On a quarterly basis MA PMP staff convene to review the search activity records from multiple sources.

- PMP SQL database
  - Daily user activity extract files
  - Weekly Gateway (Integration) audit files
- SAS analytics
- Tableau
- Search counts are reconciled across each source reference, and any discrepancies are discussed with our vendor

# MassPAT Registration

***All MA licensed prescribers must be registered and check MassPAT if they prescribe a Schedule II or III opioid or a benzodiazepine medication.***

## ***PMP INITIATIVE: Data presented for Q2 and Q3 CY 2023\****

- Identify prescribers who wrote Schedule II-III opioid or benzodiazepine medications and are not registered with MassPAT (n = 228 individuals) in most recent two quarters\*.
- Confirm that prescribers are not registered: search by name or email address.
- Email prescribers [twice] to notify them of failure to comply (n = 206 individuals).
- Call remaining unregistered prescribers (58 individuals).
- Place hold on MCSR renewals for remaining unregistered prescribers (6 individuals).
- Almost 97% of the initial group is registered, exempt, or stopped prescribing in MA.

# MassPAT Registration (Continued)

<b>Outreach to Unregistered Prescribers in MA</b>	
Stopped Prescribing in MA	14
Exempt (VA or Hospice)	8
Registered with different name or DEA/role	22
MCSR hold placed	6
Registered	177
Outstanding	1

<sup>1</sup> Identified prescribers who prescribed C2-3 opioids or benzodiazepine medications in Q2 or Q3, CY 2023

# Buprenorphine Prompt

## The Issue:

- Buprenorphine is used to treat opioid addiction and dependence.
- Missed refill appointments are a red flag for discontinuation that is often not addressed by prescribers due to resource constraints for tracking missed appointments and outreach.
- Poor adherence to buprenorphine protocols for individuals diagnosed with OUD often results in relapse and risk of both non-fatal and fatal overdose.

# Buprenorphine Prompt (Continued)

## The Proposal:

- Buprenorphine dispensation data available in the MA PMP can identify patients who experience a lapse in treatment.
- The MA PMP received funding from the Department of Justice's Bureau of Justice Assistance (BJA) to develop functionality that alerts prescribers and delegates when there is a pre-determined gap in buprenorphine dispensing.

# Buprenorphine Prompt (Continued)

## **The Proposal (continued):**

- MA PMP will work with our vendor Bamboo Health and consult with buprenorphine prescribers and other experts to develop functionality that will assist prescribers in treating patients with OUD.


# Buprenorphine Prompt (Continued)

## The Plan:

There are four primary workstreams for this project:

1. Identify patients who experience a gap in medication through dispensation submissions to the MAPMP.
2. Develop a solution that includes the ability for a prescriber and/or active delegate to receive a prompt/alert when their patient experiences a gap in prescribed buprenorphine.
3. Display the alert on the MassPAT dashboard.
4. Display the alert on a patient report on MassPAT and through Gateway.


# Trends in Stimulant Prescribing



Source: MDPH, MA PMP




# Trends in Stimulant Prescribing (Continued)



Source: MDPH, MA PMP

# Trends in Stimulant Prescribing (Continued)

	Stimulant Rx			% Change	% Change
	2011	2019	2020	2011: 2019	2011: 2020
< 12 Yrs	258,780	273,023	232,810	5.5	-10.0
12-18 Yrs	325,575	374,001	324,878	14.9	-0.2
19-24 Yrs	183,584	210,036	204,081	14.4	11.2
25-34 Yrs	233,017	510,801	524,567	119	125
35-44 Yrs	159,911	403,519	441,402	152	176
45-54 Yrs	155,582	298,397	312,541	92	101
55-64 Yrs	99,441	206,074	216,031	107	117
> 64 Yrs	31,513	86,999	93,501	176	197




Source: MDPH, MA PMP

# Trends in Activity of Concern?

## Multiple Provider Episodes

Activity of Concern is often referred to as doctor/pharmacy shopping or multiple provider episode. Do all states share similar trends?



Source: MDPH, MA PMP



# Massachusetts Department of Public Health

## Thank You

**Massachusetts Prescription Monitoring Program**

**Email: [mapmp.dph@mass.gov](mailto:mapmp.dph@mass.gov)**

**Phone: (617) 753-7310**